Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$4.25 - $10.4 $105,871 - $259,074
-24,911 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$8.02 - $32.01 $511,908 - $2.04 Million
-63,829 Reduced 71.93%
24,911 $660,000
Q4 2020

Feb 11, 2021

BUY
$4.23 - $8.73 $375,370 - $774,700
88,740 New
88,740 $674,000

Others Institutions Holding RUBY

About Rubius Therapeutics, Inc.


  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Hite Hedge Asset Management LLC Portfolio

Follow Hite Hedge Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hite Hedge Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hite Hedge Asset Management LLC with notifications on news.